Product Release Vetter Dual-Chamber Technology
For complex compounds that require lyophilization, Vetter offers two efficient and user-friendly systems.
Vetter dual-chamber technology
For complex compounds that require lyophilization, Vetter offers two efficient and user-friendly systems: the dual-chamber Vetter Lyo-Ject® syringe and dual-chamber V-LK® cartridge. Lyophilized drug resides in one chamber; diluent in the other. The drug is reconstituted just prior to administration in a few simple steps. Why dual-chamber technology? Simple administration, precise dosing, and increased API yield, due to reduced overfill requirements.
Dosage forms:
In addition to lyophilized-drug/diluent combinations, dual-chamber systems may also be used for liquid/liquid or powder/liquid drug combinations.
Sizes:
Dual-chamber syringe: in 1 ml, 2.5 ml and 5 ml sizes, covering fillvolumes of 0.1 ml - 5 ml per chamber
Dual-chamber cartridge: in 1.5 ml size, covering fill volumes of 0.1 ml - 1.4 ml (first chamber) and 0.1 ml - 1.3 ml (second chamber)
Click here for more information.
For US inquiries please call +1-847-581-6888.
For EU inquiries please call +49-751-3700-0.
info@vetter-pharma.comwww.vetter-pharma.com
Drug Solutions Podcast: Novel Drug Delivery Approaches: Refining AAV Vector Deliveries
May 30th 2025In this podcast episode, we discuss novel approaches to drug delivery, specifically regarding adeno-associated virus (AAV) vectors, as viewed by two industry experts who recently exhibited at the annual ASGCT meeting.
Transformations in Drug Development for Cell and Gene Therapies
March 28th 2025As a recognized leader in immunophenotyping for clinical trials, Kevin Lang from PPD discusses how spectral flow cytometry is transforming drug development, particularly in cell and gene therapies like CAR-T. He also dives into his award-winning research, including his 2024 WRIB Poster Award-winning work, and his insights from presenting at AAPS PharmSci360.
Hesperos, Psilera Agree to Accelerate Organ-on-a-Chip Treatment for Frontotemporal Dementia
June 9th 2025The partnership leverages the Hesperos organ-on-a-chip platform in the preclinical development of Psilera’s lead compound targeting the progressive neurological disorder for which treatment options are few.
